Prophylaxis of thromboembolic complications in oncological patients treated for anemia – practical aspects of treatment of anemia in oncology Review article
Article Sidebar
Published:
Sep 30, 2017
Keywords:
venous thromboembolism, anemia, neoplasms, prophylaxis, granulocyte colony-stimulating factor
Main Article Content
Abstract
Before initiating anticoagulant prophylaxis in patients with malignant tumors, who are undergoing palliative chemotherapy, the risk of thromboembolic complications should be evaluated with the Khorany model and based on the presence of other risk factors for venous thromboembolism. In high-risk patients, there’s should be given consideration to the inclusion of anticoagulant prophylaxis.
Article Details
How to Cite
Tokajuk, P. (2017). Prophylaxis of thromboembolic complications in oncological patients treated for anemia – practical aspects of treatment of anemia in oncology. Medycyna Faktow (J EBM), 10(3(36), 227-232. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2129
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wojtukiewicz M.Z., Sierko E., Tomkiewski W. et al.: Wytyczne dotyczące profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej u chorych na nowotwory poddawanych leczeniu zachowawczemu. Onkol. Prakt. Klin. Edu. 2016; 2(3): 73-101.
2. Zawilska K., Bała M., Błędowski D.W. et al.: Polskie wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej – aktualizacja 2012. Med. Prakt. 2012; 5: 9-19.
3. Wojtukiewicz M.Z., Sierko E.: Zakrzepy a nowotwory. W: Windyga J., Pasierski T., Torbicki A. (red.): Zakrzepy i zatory. Wyd. III. Wydawnictwo Lekarskie PZWL, Warszawa 2014: 85-106.
4. Mandala M., Falanga A., Roila F.; ESMO Guidelines Working Group: Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2011; 22(suppl. 6): vi85-vi92.
5. Lyman G.H., Khorana A.A., Kuderer N.M. et al.: Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. JCO 2013; 31(17): 2189-2204.
6. Wojtukiewicz M.Z., Sierko E.: Zaburzenia hemostazy u chorych na nowotwory. W: Krzakowski M. (red.): Onkologia Kliniczna. Tom I. Wyd. II, rozszerzone. Wydawnictwo Medyczne BORGIS, Warszawa 2006: 444-476.
7. Wojtukiewicz M.Z., Sierko E.: Zaburzenia hemostazy u chorych na nowotwory. W: Jeziorski A., Szawłowski A.W., Towpik E. (red.): Chirurgia Onkologiczna. Wyd. I. Wydawnictwo Lekarskie PZWL, Warszawa 2009: 185-204.
8. Khorana A.A., Kuderer N.M., Culakova E. et al.: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
9. Lee A.Y.Y.: Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am. Soc. Hematol. Educ. Program 2010; 2010: 144-149.
10. Levitan N., Dowlati A., Remick S.C. et al.: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78(5): 285-291.
11. Prandoni P., Lensing A.W., Piccioli A. et al.: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
12. Khorana A.A.: Cancer and thrombosis: implications of published guidelines for clinical practice. Ann. Oncol. 2009; 20: 1619-1630.
13. Khorana A.A.: Cancer-associated thrombosis: updates and controversies. Hematology Am. Soc. Hematol. Educ. Program 2012; 2012: 626-630.
14. Agnelli G., Gussoni G., Bianchini C. et al.: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10): 943-949.
15. Bennett C.L., Silver S.M., Djulbegovic B. et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
16. Leyland-Jones B., Bondarenko I., Nemsadze G.: A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. J. Clin. Oncol. 2016; 34: 1197-1207.
17. Aapro M., Leonard R.C., Barnadas A. et al.: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J. Clin. Oncol. 2008; 26: 592-598.
18. Agnelli G., George D.J., Kakkar A.K. et al.: Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N. Engl. J. Med. 2012; 366: 601-609.
19. Agnelli G., Gussoni G., Bianchini C. et al.: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10: 943-949.
20. Agnelli G., Verso M.: Management of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 2011; 9(suppl. 1): 316-324.
21. Pelzer U., Opitz B., Deutschinoff G. et al.: Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J. Clin. Oncol. 2015; 33: 2028-2034.
22. Akl E.A., Kahale L.A., Hakoum M.B.: Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst. Rev. 2017; 9: CD006652.
2. Zawilska K., Bała M., Błędowski D.W. et al.: Polskie wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej – aktualizacja 2012. Med. Prakt. 2012; 5: 9-19.
3. Wojtukiewicz M.Z., Sierko E.: Zakrzepy a nowotwory. W: Windyga J., Pasierski T., Torbicki A. (red.): Zakrzepy i zatory. Wyd. III. Wydawnictwo Lekarskie PZWL, Warszawa 2014: 85-106.
4. Mandala M., Falanga A., Roila F.; ESMO Guidelines Working Group: Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2011; 22(suppl. 6): vi85-vi92.
5. Lyman G.H., Khorana A.A., Kuderer N.M. et al.: Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. JCO 2013; 31(17): 2189-2204.
6. Wojtukiewicz M.Z., Sierko E.: Zaburzenia hemostazy u chorych na nowotwory. W: Krzakowski M. (red.): Onkologia Kliniczna. Tom I. Wyd. II, rozszerzone. Wydawnictwo Medyczne BORGIS, Warszawa 2006: 444-476.
7. Wojtukiewicz M.Z., Sierko E.: Zaburzenia hemostazy u chorych na nowotwory. W: Jeziorski A., Szawłowski A.W., Towpik E. (red.): Chirurgia Onkologiczna. Wyd. I. Wydawnictwo Lekarskie PZWL, Warszawa 2009: 185-204.
8. Khorana A.A., Kuderer N.M., Culakova E. et al.: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
9. Lee A.Y.Y.: Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am. Soc. Hematol. Educ. Program 2010; 2010: 144-149.
10. Levitan N., Dowlati A., Remick S.C. et al.: Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78(5): 285-291.
11. Prandoni P., Lensing A.W., Piccioli A. et al.: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
12. Khorana A.A.: Cancer and thrombosis: implications of published guidelines for clinical practice. Ann. Oncol. 2009; 20: 1619-1630.
13. Khorana A.A.: Cancer-associated thrombosis: updates and controversies. Hematology Am. Soc. Hematol. Educ. Program 2012; 2012: 626-630.
14. Agnelli G., Gussoni G., Bianchini C. et al.: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10): 943-949.
15. Bennett C.L., Silver S.M., Djulbegovic B. et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924.
16. Leyland-Jones B., Bondarenko I., Nemsadze G.: A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. J. Clin. Oncol. 2016; 34: 1197-1207.
17. Aapro M., Leonard R.C., Barnadas A. et al.: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J. Clin. Oncol. 2008; 26: 592-598.
18. Agnelli G., George D.J., Kakkar A.K. et al.: Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N. Engl. J. Med. 2012; 366: 601-609.
19. Agnelli G., Gussoni G., Bianchini C. et al.: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10: 943-949.
20. Agnelli G., Verso M.: Management of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 2011; 9(suppl. 1): 316-324.
21. Pelzer U., Opitz B., Deutschinoff G. et al.: Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J. Clin. Oncol. 2015; 33: 2028-2034.
22. Akl E.A., Kahale L.A., Hakoum M.B.: Parenteral anticoagulation in ambulatory patients with cancer. Cochrane Database Syst. Rev. 2017; 9: CD006652.